首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5248篇
  免费   382篇
  国内免费   18篇
耳鼻咽喉   90篇
儿科学   207篇
妇产科学   65篇
基础医学   526篇
口腔科学   102篇
临床医学   385篇
内科学   987篇
皮肤病学   189篇
神经病学   332篇
特种医学   209篇
外国民族医学   2篇
外科学   907篇
综合类   131篇
一般理论   6篇
预防医学   307篇
眼科学   143篇
药学   625篇
中国医学   40篇
肿瘤学   395篇
  2023年   40篇
  2022年   48篇
  2021年   180篇
  2020年   116篇
  2019年   151篇
  2018年   185篇
  2017年   108篇
  2016年   157篇
  2015年   155篇
  2014年   195篇
  2013年   259篇
  2012年   408篇
  2011年   384篇
  2010年   216篇
  2009年   189篇
  2008年   312篇
  2007年   287篇
  2006年   281篇
  2005年   249篇
  2004年   222篇
  2003年   211篇
  2002年   162篇
  2001年   130篇
  2000年   110篇
  1999年   102篇
  1998年   31篇
  1997年   29篇
  1996年   26篇
  1995年   33篇
  1994年   27篇
  1993年   30篇
  1992年   72篇
  1991年   67篇
  1990年   48篇
  1989年   43篇
  1988年   49篇
  1987年   36篇
  1986年   32篇
  1985年   46篇
  1984年   38篇
  1983年   22篇
  1982年   12篇
  1981年   12篇
  1979年   21篇
  1978年   11篇
  1974年   9篇
  1973年   8篇
  1972年   10篇
  1971年   12篇
  1968年   9篇
排序方式: 共有5648条查询结果,搜索用时 15 毫秒
1.
目的探讨胆总管结石患者采用内镜逆行胰胆管造影术(ERCP)取石后同期开展胆道支架置入术或开展经内镜鼻胆管引流术(ENBD),对于防范并发症的价值。 方法按照前瞻性研究原则,选择2017年4月至2019年1月新疆医科大学第一附属医院收治的338例胆总管结石患者,随机分为支架组(170例)与引流组(168例)。两组患者均行ERCP治疗,其中引流组术后同期开展ENBD,支架组患者术后开展胆道支架置入术,对比两组患者腹痛评分、并发症发生情况及预后。 结果两组患者术后均未合并严重出血、穿孔或病死,结石完全清除率差异无统计学意义。与支架组相比,引流组术中胰腺管插管次数,术后4 h血淀粉酶水平、高淀粉酶血症、急性胰腺炎以及并发症总发生率更高,差异有统计学意义(P<0.05),术后24、48、72 h不同时点腹痛测评分值居更高水平(P<0.05)。 结论对于胆总管结石行ERCP治疗的患者,术后予以ENBD、胆道支架置入术的结石完全清除效果对比无明显差异,但胆道支架置入术更能降低术后并发症风险、缓解腹痛症状,患者获益更多。  相似文献   
2.
3.
Introduction: In early childhood, wheezing due to lower respiratory tract illness is often associated with infection by commonly known respiratory viruses such as respiratory syncytial virus (RSV) and human rhinovirus (RV). How respiratory viral infections lead to wheeze and/or asthma is an area of active research.

Areas covered: This review provides an updated summary of the published information on the development of post-viral induced atopy and asthma and the mechanisms involved. We focus on the contribution of animal models in identifying pathways that may contribute to atopy and asthma following respiratory virus infection, different polymorphisms that have been associated with asthma development, and current options for disease management and potential future interventions.

Expert commentary: Currently there are no prophylactic therapies that prevent infants infected with respiratory viruses from developing asthma or atopy. Neither are there curative therapies for patients with asthma. Therefore, a better understanding of genetic factors and other associated biomarkers in respiratory viral induced pathogenesis is important for developing effective personalized therapies.  相似文献   

4.
Multiple opioids are known to trigger mast cell degranulation. We report the case of a neonate with blistering skin lesions at birth who died of multi‐organ failure after administration of morphine. Given the excessive histamine release and potential complications associated with morphine administration, alternative opioids and adjuvants should be considered in infants presenting with evidence of bullous or infiltrative skin lesions until mastocytosis is ruled out.  相似文献   
5.
6.
As the COVID-19 pandemic continues to claim lives across the globe, insufficient data exists regarding the optimal treatment. It is well known that patients 55 years of age or older and patients with certain chronic diseases are at higher risk of severe illness, including acute respiratory distress syndrome and death. A potentially fatal pulmonary complication of sickle cell disease, acute chest syndrome, can be precipitated by acute infections, including respiratory viruses. We report the case of a patient with sickle cell disease (HbSC) who developed COVID-19 pneumonia and acute chest syndrome who was treated with emergent red blood cell exchange in order to avoid endotracheal intubation.  相似文献   
7.
ObjectivesTo characterize and compare the stability of cortical potentials evoked by deep brain stimulation (DBS) of the subthalamic nucleus (STN) across the naïve, parkinsonian, and pharmacologically treated parkinsonian states. To advance cortical potentials as possible biomarkers for DBS programming.Materials and MethodsSerial electrocorticographic (ECoG) recordings were made more than nine months from a single non-human primate instrumented with bilateral ECoG grids spanning anterior parietal to prefrontal cortex. Cortical evoked potentials (CEPs) were generated through time-lock averaging of the ECoG recordings to DBS pulses delivered unilaterally in the STN region using a chronically implanted, six-contact, scaled DBS lead. Recordings were made across the naïve followed by mild and moderate parkinsonian conditions achieved by staged injections of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin. In addition to characterizing the spatial distribution and stability of the response within each state, changes in the amplitude and latency of CEP components as well as in the frequency content were examined in relation to parkinsonian severity and dopamine replacement.ResultsIn the naïve state, the STN DBS CEP presented as a multiphase response maximal over M1 cortex, with components attributable to physiological activity distinguishable from stimulus artifact as early as 0.45–0.75 msec poststimulation. When delivered using therapeutically effective parameters in the parkinsonian state, the CEP was highly stable across multiple recording sessions within each behavioral state. Across states, significant differences were present with respect to both the latency and amplitude of individual response components, with greater differences present for longer-latency components (all p < 0.05). Power spectral density analysis revealed a high-beta peak within the evoked response, with significant changes in power between disease states across multiple frequency bands.ConclusionsOur findings underscore the spatiotemporal specificity and relative stability of the DBS-CEP associated with different disease states and with therapeutic benefit. DBS-CEP may be a viable biomarker for therapeutic programming.  相似文献   
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号